Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Conditions:   Squamous Cell Carcinoma of the Oropharynx;   Squamous Cell Carcinoma of the Larynx;   Squamous Cell Carcinoma of the Oral Cavity;   Squamous Cell Carcinoma of the Hypopharynx;   Squamous Cell Carcinoma of the Paranasal Sinus;   Head and Neck Squamous Cell Car cinoma;   Squamous Cell Cancer;   Head and Neck Carcinoma Interventions:   Drug: Nivolumab;   Drug: Cetuximab Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   James and Esther King Biomedical Research Program;   Eli Lilly and Company Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials